Business Strategy

PlaqueTec is capitalising on the lack of biomarkers available to inform the development of new cardiovascular drugs. Its proprietary technology can be used to:

  • assess the performance and potential differentiation of existing drugs;
  • facilitate the development of new drugs;
  • better understand mechanisms for treatment of CAD;
  • develop patient-specific information and more accurately predict the risk of heart attack; and
  • stratify target populations for specific drug therapies.

PlaqueTec is currently providing pharma with access to its unique biomarker data.